Editorial
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Mar 16, 2024; 12(8): 1388-1394
Published online Mar 16, 2024. doi: 10.12998/wjcc.v12.i8.1388
Immunoglobulin A glomerulonephropathy: A review
Mohamad El Labban, Salim Surani
Mohamad El Labban, Department of Internal Medicine, Mayo Cliic Health System, Mankato, MN 56001, United States
Salim Surani, Department of Medicine & Pharmacology, Texas A&M University, College Station, TX 77843, United States
Author contributions: El Labban M was involved in writing the initial draft and revision; Surani S was involved in idea generation, write up, revision, and supervision.
Conflict-of-interest statement: None of the authors have any conflict of interest to disclose.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Salim Surani, FCCP, MD, Professor, Department of Medicine & Pharmacology, Texas A&M University, No. 40 Bizzell Street, College Station, TX 77843, United States. srsurani@hotmail.com
Received: December 11, 2023
Peer-review started: December 11, 2023
First decision: January 25, 2024
Revised: January 27, 2024
Accepted: February 25, 2024
Article in press: February 25, 2024
Published online: March 16, 2024
Processing time: 92 Days and 1.3 Hours
Core Tip

Core Tip: Immunoglobulin A nephropathy is the most common type of glomerulonephritis globally. The management approach differs based on the level of risk for renal disease progression. In low-risk settings, patients are treated with angiotensin system blockade, while patients with a high risk of progressive renal disease are treated with immunosuppressive therapy. Systemic steroids have been shown to have favorable outcomes when compared to the standard of care in high-risk patients. Unfortunately, steroids are associated with numerous side effects. In some studies, mycophenolate mofetil has been shown to have favorable outcomes when compared to steroids with a better safety profile.